MedTrace Logo

Early and Late Neutrophil CD64 and Monocyte HLA-DR as Biomarkers for Septic Shock

NCT07401329 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2026-02-10

No results posted yet for this study

Summary

Study Summary: Neutrophil CD64 \& Monocyte HLA-DR in Septic Shock

What is studied?

Doctors looked at two blood markers:

* Neutrophil CD64 (nCD64): rises quickly when the body fights infection.
* Monocyte HLA-DR (mHLA-DR): falls when the immune system becomes weak or "paralyzed." They also calculated a Sepsis Index (ratio of nCD64 to HLA-DR) to see how these markers change in patients with septic shock.

Why is this important? Septic shock is a severe form of sepsis that can cause organ failure and death. Early detection and knowing which patients are at higher risk can guide treatment and improve survival.

How was it done?

* Blood samples were taken on Day 1 (early) and Day 8 (late).
* Results will be compared between survivors and non-survivors.
* 20 healthy people provided baseline values for comparison.

What does this mean? - Monitoring these markers over time (not just once) may helps doctors understand whether a patient's immune system is recovering or worsening.

Take-home message

For patients and families:

\- Septic shock is serious, but doctors now have better tools to track how the body is responding.

Conditions

Sponsors & Collaborators

  • Pandit Bhagwat Dayal Sharma, PGIMS, Rohtak

    lead OTHER

Principal Investigators

  • Dhruva Chaudhry, MBBS,MD,DM · Pandit BD Sharma Postgraduate Institute of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-05
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07401329 on ClinicalTrials.gov